Skip to content

Now let me check for any guidance documents about complex annotation in GO-CAM models:

Let me analyze the model based on my findings. I'll first provide a summary of what the model represents:

Review of GO-CAM model 65c57c3400001478

Model Overview

This model titled "Negative regulation of Hippo signaling by SLMAP-STRIPAK complex (Human)" represents a molecular pathway in human cells where the SLMAP-STRIPAK complex negatively regulates the Hippo signaling pathway.

The model features four main activities: 1. Protein serine/threonine phosphatase activity (GO:0004722) enabled by a FAR/SIN/STRIPAK complex (GO:0090443) 2. Protein serine/threonine kinase activity (GO:0004674) enabled by STK3/MST2 (UniProtKB:Q13188) 3. Protein-macromolecule adaptor activity (GO:0030674) enabled by SLMAP (UniProtKB:Q14BN4) 4. Protein serine/threonine kinase activator activity (GO:0043539) enabled by SAV1 (UniProtKB:Q9H4B6)

All activities are localized in the cytoplasm (GO:0005737) and participate in either negative regulation of Hippo signaling (GO:0035331) or Hippo signaling (GO:0035329).

Scientific Accuracy Assessment

The model is well-supported by the scientific literature. The central paper cited (PMID:29063833) provides solid evidence for the mechanism depicted, showing how SLMAP promotes binding of the STRIPAK-PP2A phosphatase complex to MST2, leading to dephosphorylation of its activation loop and inhibition of Hippo signaling. SAV1 antagonizes this by inhibiting the phosphatase activity, promoting MST2 activation.

The other cited papers (PMID:15688006 and PMID:35429439) provide additional context on MST2/STK3's role in activating LATS kinases and the involvement of SAV1 in this process.

GO-CAM Model Structure Review

Strengths:

  1. Appropriate causal relationships: The model correctly represents that SLMAP provides input for (RO:0002413) the phosphatase activity of the STRIPAK complex, which directly negatively regulates (RO:0002630) STK3/MST2 kinase activity. This aligns with the literature showing SLMAP as an adaptor that recruits STRIPAK to MST2.

  2. Complex representation: The model appropriately uses a GO term for the complex (GO:0090443 - FAR/SIN/STRIPAK complex) as the enabler of the phosphatase activity, while showing only PPP2CA (P67775) as a member. This is consistent with best practices for representing complexes when the exact subunit carrying the activity is known (PPP2CA is the catalytic subunit of PP2A).

  3. Dual regulation of STK3/MST2: The model correctly represents the antagonistic regulation of MST2 by both SAV1 (positive regulation) and the STRIPAK complex (negative regulation).

Areas for Improvement:

  1. Complex representation: While the model uses GO:0090443 (FAR/SIN/STRIPAK complex) with only PPP2CA listed as a member, it might be beneficial to include other known components of the STRIPAK complex that are mentioned in the paper (like STRIP1). According to the complex annotation guidelines, since PPP2CA is the main catalytic component, the current representation is acceptable, but including additional subunits would provide more detail.

  2. Molecular details: The model doesn't capture some mechanistic details from the literature, such as the autophosphorylation of MST2 at specific sites in the linker region (T336, T378) that create binding sites for SLMAP via its FHA domain.

  3. Downstream effects: While the model focuses on SLMAP-STRIPAK's negative regulation of MST2, it could be extended to show how this ultimately affects LATS kinases and YAP/TAZ.

Compliance with GO-CAM Best Practices

The model follows key GO-CAM best practices: - Activities are properly connected with appropriate causal relations - Protein-enabled activities have appropriate molecular function terms - Activities are properly localized to cellular components - Activities are organized within appropriate biological processes - Evidence is properly cited with supporting literature

The representation of the STRIPAK complex follows the guidelines for complex annotation, using the appropriate GO term for the complex (GO:0090443) with the catalytic subunit (PPP2CA) specified.

Conclusion

The GO-CAM model 65c57c3400001478 accurately represents the negative regulation of Hippo signaling by the SLMAP-STRIPAK complex as described in the scientific literature. The model appropriately depicts the antagonistic roles of SLMAP-STRIPAK and SAV1 in regulating MST2/STK3 activity, which is central to Hippo pathway activation.

The model follows GO-CAM best practices and uses appropriate terms and relations to represent the molecular mechanisms involved. While some additional details could be incorporated, the current model provides a clear and accurate representation of this regulatory mechanism.